Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Palantir Technologies

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

- PMLiVE

Conversation everywhere, but ‘in real life’ too

Technological advances have made it easier for client–agency teams working in Europe and globally to connect but as social animals humans still get the best out of one another when...

- PMLiVE

Merck KGaA starts third phase III trial for cancer hope TH-302

Unique method of action to target cells with low oxygen levels

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

- PMLiVE

Eric Green named NIH’s data science lead

Takes role on interim basis as part of expanding plans for data

European adoption of physician-only social networks growing

UK showed clear lead in use last year, according to Manhattan Research

Virgo Health and GolinHarris launch digital initiative

Go Digital Health team comprises healthcare communicators and digital specialists

UK outlines pipedream of a paperless health service

Health secretary issues empty 'challenge' for NHS to make better use of IT

- PMLiVE

Lundbeck launches Chorea Matters online resource

Includes recognising chorea education programme

More than half of US adults go online for health information

And more than a third use internet for self-diagnosis

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links